Dracen announces two DRP-104 presentations at AACR

Posters characterize MOA and consistent single agent activity in KEAP1 mutant tumors

Dracen Pharmaceuticals Inc., announced today that two posters profiling its lead glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association for Cancer Research Virtual meeting. One poster describes the immuno-metabolism and anti-cancer effects of DRP-104; and, the other profiles the potent, consistent single agent activity in KEAP1 mutant tumor models of NSCLC.

“As our lead asset DRP-104 advances in phase I clinical development, our preclinical data continues to confirm its promising profile both as a single agent and in combination therapy” said Robert Wild, Ph.D. Chief Scientific Officer of Dracen Pharmaceuticals. “The data being presented at AACR demonstrates that DRP-104 has a significant direct effect on tumors as well as profound remodeling of the tumor microenvironment; the latter leading to stimulation of both the innate as well as the adaptive immune systems resulting in therapeutic synergy with checkpoint inhibitors. Additionally, DRP-104 has demonstrated potent and broad antitumor activity in both murine and patient derived lung adenocarcinoma and squamous tumor models with KEAP1 mutations. The data suggests that DRP-104 is a promising therapy to treat KEAP1 mutant lung cancers and we are excited about advancing this promising compound in the clinic.”

The presentation details are as follows:
Broad Acting Glutamine Antagonism Remodels the Tumor Microenvironment; Induces Distinctive Immune
Modulation; and, Synergizes with Immune Checkpoint Blockade
Abstract Date: June 22nd at 9:00 am – 6:00 pm
Abstract ID: 5607

Uncovering metabolic bottlenecks in KEAP1 mutant lung cancer
Abstract Date: June 22nd at 9:00 am – 6:00 pm
Abstract ID: 2569

About DRP-104
Our lead glutamine antagonist, DRP -104, is currently in early stage clinical development. The mechanisms of action for DRP-104 include: a) direct inhibition of tumor cell addiction to glutamine leading to substantial single agent activity and tumor regression; b) broad metabolic remodeling of the tumor microenvironment leading to enhanced anti-tumor immune activity; and, c) stimulation of T effector, NK and NKT cells and inhibition of immunosuppressive MDSC and macrophage cells, leading to greater long-term durable responses and survival.

About Dracen Pharmaceuticals
Dracen Pharmaceuticals, Inc. is a privately held biotech company developing proprietary anti-cancer drugs that
target immuno-metabolism. Dracen’s investors include Deerfield Management; Osage University Partners; and
The Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague). Dracen is headquartered in
New York, NY with research operations in San Diego, CA.